Understanding the Link Between Hair Relaxers and Hormone Related Cancers

Hair relaxers are widely used products designed to straighten and smooth curly or wavy hair. While these products provide convenience and a desired look for many individuals, there are growing concerns about the potential health risks associated with their use. One of these concerns is the possible link between hair relaxers and hormone-related cancers. This article will explore the connection between Hair Relaxers and Hormone Related Cancers, the potential causes of this link, and ways to reduce the risk of developing these cancers.

Hormone-Related Cancers

Hormone-related cancers are a group of cancers that are influenced by hormonal factors. Some common types of hormone-related cancers include:

1. Uterine Cancer: A cancer that begins in the uterus, often in the endometrium (the lining of the uterus).
2. Endometrial Cancer (Type I & Type II): Type I endometrial cancer is the most common form, and it is usually estrogen-dependent. Type II endometrial cancer is less common, and it is not typically associated with estrogen exposure.
3. Uterine Sarcoma: A rare type of uterine cancer that starts in the muscle and supporting tissues of the uterus.
4. Ovarian Cancer (Non-Serous & Serous): Ovarian cancer can be divided into two main subtypes, non-serous (less aggressive) and serous (more aggressive). Both types can be hormone-related.

Risk factors for hormone-related cancers may include hormonal imbalances, exposure to endocrine-disrupting chemicals, and genetic factors.

Studies Linking Hair Relaxers to Hormone-Related Cancers

Research on the potential connection between hair relaxers and hormone-related cancers has been conducted over the years, with some studies suggesting a link. Key findings from major studies include:

1. A study published in the American Journal of Epidemiology found that African American women who used hair relaxers were at a higher risk of developing uterine leiomyomata, which are non-cancerous tumors that can increase the risk of certain hormone-related cancers [1].
2. The Black Women’s Health Study found an association between hair relaxer use and increased risk of uterine leiomyomata, which can be a precursor to some hormone-related cancers [2].
3. A case-control study published in the journal Cancer Causes & Control found that women who used hair relaxers had a higher risk of developing ovarian cancer, particularly among African American women [3].

It is important to note that these studies have limitations, and more research is needed to fully understand the relationship between hair relaxers and hormone-related cancers.

Potential Causes of the Link Between Hair Relaxers and Hormone-Related Cancers

A possible explanation for the link between hair relaxers and hormone-related cancers lies in the chemical ingredients found in these products. Some ingredients in hair relaxers are known to be endocrine-disrupting chemicals (EDCs), which can interfere with hormone function and potentially contribute to the development of hormone-related cancers. Additionally, some ingredients found in hair relaxers are known or suspected carcinogens [4].

Routes of exposure to harmful chemicals in hair relaxers can include skin absorption through the scalp and inhalation during the application process. These exposure routes may increase the risk of developing hormone-related cancers.

Reducing the Risk of Hormone-Related Cancers

To minimize the potential risk of hormone-related cancers associated with hair relaxer use, consider the following tips:

1. Explore safer alternatives to hair relaxers, such as natural hair care options (e.g., using natural oils, deep conditioning treatments) or non-chemical hair straightening techniques (e.g., ceramic flat ironing, steam straightening).
2. Be cautious when selecting hair care products by carefully reading the labels and researching ingredients. Opt for products with fewer chemicals and more natural ingredients.
3. Ensure proper application and use of hair relaxers by following the manufacturer’s instructions and taking necessary precautions, such as wearing gloves during application and avoiding contact with the eyes.

Legal Options for Hair Relaxer-Related Injuries

As concerns over the potential link between hair relaxers and hormone-related cancers grow, so too has the number of hair relaxer lawsuits. Individuals who believe they have developed hormone-related cancers as a result of using hair relaxers may be eligible to seek compensation through the legal system. Types of compensation available for plaintiffs can include medical expenses, lost wages, pain and suffering, emotional distress, and other damages related to the injury.

The potential link between hair relaxers and hormone-related cancers is a serious concern that warrants further investigation. While more research is needed to fully understand this relationship, consumers should be aware of the potential risks associated with hair relaxer use and take steps to minimize their exposure to harmful chemicals. By opting for safer alternatives and being cautious when selecting hair care products, individuals can reduce their risk of developing hormone-related cancers while still enjoying the benefits of smooth, straight hair.

References:

[1] Wise, L. A., Palmer, J. R., Reich, D. E., Cozier, Y. C., & Rosenberg, L. (2012). Hair relaxer use and risk of uterine leiomyomata in African-American women. American Journal of Epidemiology, 175(5), 432-440.

[2] Wise, L. A., Palmer, J. R., & Rosenberg, L. (2011). Hair relaxer use and risk of uterine leiomyomata in African American women. American Journal of Epidemiology, 173(suppl_11), S49.

[3] Moorman, P. G., Palmieri, R. T., Akushevich, L., Berchuck, A., & Schildkraut, J. M. (2011). Ovarian cancer risk factors in African-American and white women. American Journal of Epidemiology, 174(4), 405-416.

[4] Helm, J. S., Nishioka, M., Brody, J. G., Rudel, R. A., & Dodson, R. E. (2018). Measurement of endocrine disrupting and asthma-associated chemicals in hair products used by Black women. Environmental Research, 165, 448-458.